Weekly Neurology Deep Dive - A review of recent impactful publications in the field of Neurology

This comprehensive clinical review examines the extensive neurological complications associated with multiple myeloma, ranging from common peripheral nerve damage to rare central nervous system involvement. The text details how peripheral neuropathy frequently arises from both the disease itself and neurotoxic treatments like bortezomib, often requiring dose adjustments or shifts to subcutaneous administration. Beyond nerve damage, the sources outline critical emergencies such as epidural spinal cord compression and metabolic issues like hyperammonemic encephalopathy. Specialized conditions, including AL amyloidosis, POEMS syndrome, and leptomeningeal disease, are analyzed regarding their unique diagnostic markers and survival rates. Modern management strategies are highlighted, emphasizing the use of immunotherapies, radiation, and targeted systemic drugs to improve patient outcomes. Ultimately, the text serves as a detailed guide for identifying and treating the diverse neuropsychiatric and physical impairments that affect this patient population.

The provided text outlines the 2026 clinical guidelines for managing aneurysmal subarachnoid haemorrhage (aSAH), a severe type of stroke caused by a ruptured brain aneurysm. Developed by several European medical societies, the document establishes standardized protocols to reduce the high rates of death and disability associated with this condition. The guidelines prioritize early intervention, specifically recommending that aneurysms be treated within 24 hours of the initial rupture. Endovascular coiling is generally favored over surgical clipping for patients in stable condition when both options are viable. Furthermore, the sources emphasize specialized care in high-volume neuro-ICUs and advocate for the use of oral nimodipine to prevent secondary brain damage. Conversely, the authors advise against the routine use of several common treatments, such as antifibrinolytic drugs and statins, due to a lack of proven benefit.

This comprehensive review details the neurological assessment and management of autonomic failure, focusing specifically on neurogenic orthostatic hypotension (nOH). The text explains that this condition arises when nervous system damage prevents the body from maintaining stable blood pressure upon standing, often due to neurodegenerative synucleinopathies like Parkinson disease or multiple system atrophy. To diagnose these disorders, clinicians utilize orthostatic vital signs, specialized laboratory screenings, and advanced neuroimaging to differentiate between primary autonomic failures and other causes. Treatment strategies prioritize improving quality of life rather than achieving perfect blood pressure readings, starting with non-pharmacological interventions like increased salt intake and compression garments. For persistent symptoms, the sources outline various FDA-approved and off-label medications, such as midodrine and droxidopa, tailored to the patient’s specific pathophysiological profile. Ultimately, the review serves as a clinical guide for identifying the underlying triggers of fainting and dizziness while managing the complex balance of standing and supine blood pressure.

Intracranial arterial dolichoectasia (IADE) is a vascular condition defined by the abnormal widening, lengthening, and twisting of arteries within the brain, most frequently affecting the basilar artery. This review explores how the disease stems from structural arterial wall damage caused by genetic factors, hemodynamic stress, and enzyme imbalances. Patients may remain asymptomatic or suffer from severe complications such as ischemic strokes, brain hemorrhages, or nerve compression. Doctors typically diagnose the condition using MRI and MRA scans, often applying the Smoker’s criteria to measure vessel distortion. Because there is currently no specific cure to stop arterial expansion, medical management centers on controlling blood pressure and using antithrombotic medications. For high-risk cases involving rapid growth or physical pressure on brain structures, surgical or endovascular procedures may be considered despite a lack of robust clinical evidence.

This 2026 systematic review investigates whether N-acetylcysteine (NAC) can serve as an effective neuroprotective treatment for patients suffering from ischemic stroke. By analyzing several clinical trials, the authors explore how the drug’s antioxidant and anti-inflammatory properties might mitigate brain damage during the critical hours following a blockage. While initial data suggests NAC may improve neurological scores and stabilize certain biochemical markers, the overall findings remain inconclusive due to small sample sizes and inconsistent results across studies. The researchers conclude that while the medication appears safe and biologically promising, its status as a standard clinical therapy is not yet supported. Consequently, the paper calls for larger, more rigorous trials to determine the optimal dosing and timing required to protect the brain effectively alongside existing reperfusion therapies.

This clinical trial investigated the efficacy and safety of a combined vitamin B treatment for patients with cognitive impairment undergoing maintenance hemodialysis. Researchers conducted a prospective, double-blind study where 215 participants received either a daily dose of thiamin and folic acid or a placebo for nearly two years. The results showed that the treatment group experienced significant cognitive improvement across multiple domains, including memory and executive function, alongside a notable reduction in homocysteine levels. Furthermore, while mortality rates remained comparable between the two groups, those receiving supplements reported a significantly lower incidence of cardiovascular and cerebrovascular adverse events. The study concludes that high-dose thiamin and folic acid supplementation is a safe and effective therapy for addressing neurological complications in dialysis patients.

The two papes reviewed here discuss advances in the treatment of of autoimmune nodopathy (AN), a rare neurological condition formerly grouped with chronic inflammatory demyelinating polyradiculoneuropathy. Unlike traditional cases, AN involves pathogenic IgG4 autoantibodies that target specific proteins at the nodes of Ranvier, making patients largely resistant to standard treatments like intravenous immunoglobulin. Research involving 118 patients reveals a high clinical response rate of 92% for those receiving B-cell depleting therapies such as rituximab and ofatumumab. While the therapy appears highly effective for subtypes like anti-NF155 and anti-CNTN1, the sources report a safety profile that includes risks of serious infection and rare fatalities. Ultimately, the authors conclude that while results are promising, the lack of randomized controlled trials means these findings are not yet practice-changing. Further prospective studies are required to establish standardized dosing and confirm the long-term safety of this precision medicine approach.

This comprehensive medical review examines recent developments in the diagnosis, pathophysiology, and management of Guillain-Barré syndrome (GBS), an autoimmune disorder causing acute paralysis. The authors highlight a transition toward a molecular understanding of the disease, emphasizing the role of antecedent infections like Campylobacter jejuni and the identification of specific anti-ganglioside antibodies. While the text reviews established prognostic models and emerging fluid biomarkers like neurofilament light chain, it acknowledges that GBS remains primarily a clinical diagnosis. Regarding treatment, the source details updated 2023 guidelines that favor standard immunotherapies while explicitly advising against repeat immunoglobulin courses or corticosteroids. Finally, the authors evaluate the current clinical trial landscape, investigating novel but as-yet unproven targeted therapies such as complement inhibitors and neonatal Fc receptor blockades.

This article explores the potential of GLP-1 receptor agonists as a novel treatment for idiopathic intracranial hypertension (IIH), a condition traditionally managed through difficult weight loss and poorly tolerated medications. Researchers highlight a recent study suggesting these drugs may improve headaches and optic nerve swelling, possibly by directly influencing cerebrospinal fluid production rather than just through weight reduction. Despite these promising results, the authors remain cautious due to methodological limitations in current data, such as short follow-up periods and inconsistent patient coding. They also address global accessibility and insurance barriers, noting that high costs often prevent those from deprived backgrounds—who are disproportionately affected by IIH—from receiving care. Ultimately, the text calls for long-term clinical trials to determine if these therapies can officially become a standard, disease-modifying strategy for patients.

These research sources analyze the clinical profile of anti-amphiphysin-IgG-positive autoimmune syndrome, a rare paraneoplastic condition affecting the nervous system. The documentation highlights diverse clinical presentations, ranging from common manifestations like stiff-person syndrome to rare variants such as conus medullaris-cauda equina syndrome and myelitis. While the antibody often appears in isolation, its coexistence with other neural antibodies, such as AQP4-IgG or NMDAR-IgG, is shown to significantly increase the risk of underlying malignancies like breast and lung cancers. Evidence suggests that while the syndrome is severe, neurological function can be stabilized through a combination of targeted immunotherapy and oncological treatment. Ultimately, the sources emphasize that early serologic testing and long-term cancer surveillance are essential for improving patient outcomes and managing the syndrome’s complex phenotypes.

This study examines whether receiving the live-attenuated herpes zoster vaccine reduces the risk of developing dementia among older adults in Canada. Researchers utilized a natural experiment in Ontario, where government funding for the vaccine was strictly determined by specific date-of-birth eligibility thresholds. By comparing individuals born just days apart, the authors isolated the vaccine's impact from other lifestyle factors and found that eligibility led to a significant decrease in new dementia diagnoses over a five-year period. These protective effects were notably more pronounced in female participants than in males. The findings suggest that targeting neurotropic herpesviruses through immunization may be a viable strategy for maintaining neuroimmune health and delaying cognitive decline. This research provides strong evidence for a causal relationship, supporting the theory that viral reactivation plays a role in the progression of brain diseases.

The provided text outlines the 2024 European Academy of Neurology (EAN) guidelines for diagnosing adults who exhibit elevated creatine kinase levels without significant symptoms. Because this condition can stem from non-neuromuscular factors like exercise and medication or hidden genetic disorders, the authors establish a standardized testing sequence to improve diagnostic accuracy. The experts advocate for a threshold of 1.5 times the upper limit of normal to trigger further investigation, beginning with repeated measurements and the exclusion of external causes. The protocol emphasizes modern, non-invasive techniques, specifically recommending Next Generation Sequencing (NGS) and muscle MRI as primary tools over traditional muscle biopsies. Additional specialized tests, such as Dried Blood Spots for Pompe disease and electromyography, are suggested to further refine the clinical picture. Ultimately, these guidelines aim to help clinicians efficiently identify underlying muscle or nerve diseases while avoiding unnecessary invasive procedures.

Progressive multifocal leukoencephalopathy (PML) is a devastating brain infection caused by the JC virus following immune system failure. These sources detail how the virus transforms into a neurotropic phenotype to destroy brain tissue, specifically targeting subcortical white matter and creating distinct patterns on MRI scans. Diagnosis relies on the Berger criteria, which combine clinical symptoms, radiological evidence of tissue destruction, and viral detection in spinal fluid. Current management emphasizes immune reconstitution, ranging from adjusting antiretroviral therapy to using plasma exchange for drug-induced cases. Recent clinical research highlights immune checkpoint inhibitors, such as pembrolizumab, as a vital frontier in treatment. Specifically, the presence of virus-specific T cells before therapy serves as a critical biomarker, predicting significantly higher survival rates and improved functional recovery for patients.

This clinical research article investigates the effectiveness and practical management of subcutaneous immunoglobulin (SCIg) as a maintenance therapy for individuals with chronic inflammatory demyelinating polyneuropathy (CIDP). By analyzing twenty retrospective cases from various U.S. medical centers, the authors explore the transition process from intravenous to subcutaneous administration, focusing on individualized dosing strategies. The study reveals that most patients successfully maintained clinical stability after switching, often citing improved convenience and site-of-care flexibility as primary motivations. Results indicate that while a one-to-one dosing ratio is a common starting point, many patients require customized adjustments to prevent relapses or achieve the lowest effective dose. Ultimately, the research emphasizes the importance of shared decision-making and ongoing monitoring to optimize long-term outcomes and treatment tolerability.

This systematic review evaluates the optimal treatment strategies for spinal cavernous malformations, which are rare vascular lesions within the spinal cord. Researchers analyzed 50 studies involving over 2,300 patients to compare the results of surgical intervention against conservative management. While surgery was the most common approach and often led to neurological improvement, the sources highlight that surgical patients typically had more severe symptoms at the start. The study also determined a pooled annual hemorrhage rate of approximately 4.8% for these lesions. Ultimately, the authors conclude that high risk-of-bias and a lack of prospective data prevent a definitive preference for one treatment over the other. Future multicenter research is recommended to better inform clinical decisions and establish long-term outcomes.

Despite the high utility of clinical genome sequencing (GS) in diagnosing rare neurological disorders, a significant proportion of patients remain molecularly unsolved or receive results involving variants of uncertain significance (VUS). To bridge this diagnostic gap, neurologists should employ a multi-modal strategy incorporating targeted functional studies and systematic data reanalysis. When DNA sequencing identifies potentially spliceogenic variants, targeted RNA analysis using whole blood serves as an effective surrogate for inaccessible nervous tissue, enabling the reclassification of 79% of such variants and providing a molecular diagnosis for approximately 53% of these cases. Notably, transcriptomic analysis of blood is broadly applicable, as 77% of common neurodevelopmental genes exhibit sufficient expression levels in whole blood for targeted studies. For patients with initially nondiagnostic GS results, comprehensive reanalysis conducted every 12 to 24 months can achieve an additional diagnostic yield of 5.1% by applying advanced bioinformatics pipelines capable of detecting complex variants missed by standard clinical algorithms, such as short tandem repeat (STR) expansions, structural variants (SVs), and low-level mosaicism. This diagnostic process is further optimized through longitudinal phenotyping, where evolving clinical presentations are shared between the neurologist and the laboratory to inform new gene-disease associations or clarify the relevance of previously ignored variants. Implementing these integrated approaches significantly enhances clinical utility by facilitating access to precision therapies, clarifying prognosis, and providing accurate recurrence risk for families.

This comprehensive review details Spinal and Bulbar Muscular Atrophy (SBMA), a rare genetic disorder triggered by a specific mutation in the androgen receptor gene. The text explains how this defect leads to the toxic accumulation of proteins, which causes the gradual decay of both motor neurons and skeletal muscle. Beyond physical weakness and swallowing difficulties, the source highlights often-overlooked hormonal imbalances and metabolic issues that characterize the disease. Modern research emphasized here shifts the focus from a purely neurological perspective to a multi-systemic approach, identifying muscle tissue as a critical driver of the condition. Finally, the author evaluates current diagnostic tools and discusses the transition from supportive care toward promising gene-silencing therapies.

This source describes a phase 3 clinical trial evaluating the efficacy and safety of brepocitinib, an oral medication designed to treat adults with dermatomyositis. The study compared two different doses of the drug against a placebo over a one-year period, specifically focusing on patients whose condition had not responded well to previous therapies. Researchers found that the 30-mg dose significantly improved muscle strength, skin health, and overall physical function while allowing patients to reduce their reliance on steroids. Conversely, the 15-mg dose did not meet the necessary benchmarks for statistical significance compared to the placebo group. While the higher dose proved effective, it was also associated with an increased risk of serious infections compared to the other groups. Ultimately, the authors conclude that high-dose brepocitinib offers a promising new systemic treatment option for managing this complex autoimmune disease.

This study investigates the prevalence of phosphorylated alpha-synuclein (P-Syn), a key biological marker for Parkinson disease, in patients diagnosed with essential tremor (ET). Researchers found that 37% of ET patients tested positive for these protein deposits in their skin, a rate significantly higher than that found in healthy individuals. The presence of these deposits, along with higher rates of sleep disorders and smell loss, suggests that a specific group of ET patients may actually be in the early stages of a synucleinopathy. These findings indicate that skin biopsies could serve as a vital tool for identifying individuals at high risk for transitioning from a simple tremor to a more complex movement disorder. Ultimately, the research supports the theory that essential tremor may act as a precursor to Parkinson disease for some patients.

This review examines the therapeutic role of hyperbaric oxygen therapy (HBOT) as a neuromodulatory tool for treating various brain disorders. The text explains that by saturating blood plasma with supraphysiological oxygen levels, HBOT can restore mitochondrial function, reduce swelling, and trigger regenerative genetic pathways. While meta-analyses suggest significant cognitive and motor benefits for chronic traumatic brain injury, Alzheimer’s, and Parkinson’s disease, the evidence remains inconclusive or negative for conditions like multiple sclerosis, cerebral palsy, and acute stroke. A major point of academic contention involves the "sham" debate, where critics argue that low-pressure control groups are actually receiving a biologically active dose of oxygen. Ultimately, the source highlights that while HBOT is not a universal cure, it offers a promising biological intervention for specific chronic neurological repairs when administered under optimized safety protocols.

The provided text details the evolving landscape of adult glioma treatment, highlighting a significant transition from traditional histology to molecularly-driven diagnostics and targeted therapies. Recent FDA approvals have introduced precision agents such as vorasidenib for IDH-mutant tumors, dabrafenib-trametinib for BRAF-mutated cases, and dordaviprone for specific midline gliomas. While these advancements offer tangible clinical benefits and the potential to delay toxic chemoradiation, the sources note that these targets are present in only a minority of patients and are not yet curative. Beyond established treatments, the text evaluates investigational strategies focusing on DNA repair mechanisms, metabolic vulnerabilities like MTAP deletion, and advanced delivery methods such as CAR T-cell therapy. Despite this progress, researchers face persistent obstacles including the blood-brain barrier, tumor heterogeneity, and the rapid development of therapeutic resistance. Overall, the sources summarize how integrated molecular profiling is currently redefining the classification and management of primary brain tumors.

This systematic review and meta-analysis evaluates the effectiveness of modafinil in managing excessive daytime sleepiness associated with narcolepsy. By synthesizing data from multiple clinical trials, the researchers confirmed that the drug significantly improves objective wakefulness and reduces subjective drowsiness compared to placebos. The authors note that while modafinil is a first-line stimulant with a lower risk of abuse than amphetamines, it does not effectively treat cataplexy. A primary finding of the report is the lack of recent randomized controlled trials, as most foundational evidence stems from studies conducted over a decade ago. Consequently, the paper underscores a critical need for new, long-term research to better establish the medication's extended safety and comparative performance against newer therapies. Overall, the text reinforces modafinil's role in improving patient quality of life while identifying significant gaps in contemporary clinical data.

This article examines the European Medicines Agency’s recent evaluation and approval of lecanemab and donanemab, the first monoclonal antibodies authorized in the EU to slow early Alzheimer’s disease. While these therapies demonstrate a statistically significant reduction in cognitive decline, the authors highlight a complex benefit-risk assessment due to modest clinical effects and serious safety concerns like amyloid-related imaging abnormalities (ARIA). To mitigate these risks, the EMA restricted the drugs to specific patient subgroups and mandated strict MRI monitoring protocols. The text details the regulatory journey from initial rejection to approval, emphasizing that while these treatments are not cures, they represent a pivotal shift in dementia care. Ultimately, the sources stress the importance of real-world evidence and future research to refine treatment safety and explore new therapeutic targets beyond the amyloid hypothesis.

This research study evaluates the effectiveness of 18F-FDG PET/CT scans as a proactive tool for detecting hidden cancers in adults with Neurofibromatosis type 1 (NF1). While patients with this genetic disorder are highly susceptible to both benign and malignant tumors, traditional monitoring often struggles to identify aggressive transformations in early, asymptomatic stages. By reviewing a cohort of 79 patients, the authors discovered that PET/CT imaging successfully uncovered twelve incidental malignancies, including gastrointestinal and thyroid tumors, which had been missed by other methods. These findings suggest that incorporating metabolic imaging into standard surveillance protocols can facilitate earlier surgical interventions and improve long-term survival rates. The study concludes that the benefits of early cancer detection through this modality often outweigh the concerns regarding radiation exposure in adult populations. Consequently, the authors advocate for an individualized, multidisciplinary approach that utilizes PET/CT to enhance the management of NF1-related complications.

Researchers have developed a second-generation diagnostic test to identify a specific autoantibody signature that can predict multiple sclerosis (MS) years before clinical symptoms appear. By isolating a monoclonal antibody from an MS patient’s B cells, the study identified a conserved protein motif that triggers an immune response. This signature appears to result from molecular mimicry between the Epstein-Barr virus protein BRRF2 and host CNS proteins like vimentin. The refined Luminex assay uses consensus peptides to achieve high precision and can detect these markers in approximately 11% of MS cases. This tool offers a promising method for early risk assessment and the potential for preventative medical interventions.

Radiologically isolated syndrome (RIS) describes a situation where a person's brain or spinal cord scans show nerve damage typical of multiple sclerosis (MS) despite the individual having no physical symptoms. While roughly half of those identified with these incidental findings may eventually face a clinical diagnosis, others might never experience illness, making the decision to investigate or treat medically complex. To help predict health outcomes, doctors look for specific risk factors such as younger age, spinal cord involvement, or certain proteins in the spinal fluid. Recent clinical trials suggest that preventative drug therapies can significantly lower the chances of developing a first physical attack. Furthermore, the 2024 McDonald criteria have updated how the medical community classifies the condition, sometimes labeling it as early-stage biological MS to encourage proactive management. Understanding these imaging markers and refined diagnostic rules is essential for avoiding misdiagnosis while ensuring at-risk patients receive timely care.

This paper explores the medical debate regarding surgical interventions for patients facing vision loss due to idiopathic intracranial hypertension (IIH). Currently, doctors must choose between cerebrospinal fluid shunting and dural venous sinus stenting without the guidance of high-quality, comparative data. The authors highlight that existing research often suffers from publication bias or inconsistent definitions of the disease, making it difficult to determine which procedure is truly superior. To resolve this uncertainty, a new randomized controlled trial in the UK is evaluating the effectiveness and safety of both methods. The text emphasizes that optical coherence tomography provides an objective way to monitor eye swelling during these treatments. Ultimately, the goal is to move beyond personal physician preference and establish a standardized, evidence-based approach to saving a patient’s sight.

The provided text outlines a narrative review detailing how artificial intelligence is revolutionizing the discovery of biomarkers for various neurological conditions. Traditional diagnostic methods often struggle with biological complexity and delayed detection, but AI algorithms can integrate vast, multimodal datasets to identify subtle disease patterns. The sources highlight significant progress in using machine learning and deep learning to improve the diagnosis and treatment of neurovascular, neurodegenerative, and neuro-oncological disorders. For instance, AI-driven models enhance stroke outcome predictions, identify intracranial aneurysms with high sensitivity, and detect early signs of Alzheimer’s disease. Despite these breakthroughs, the text notes that clinical translation faces challenges such as dataset bias, the need for prospective validation, and the importance of algorithmic transparency. Ultimately, the research suggests that AI-based biomarkers are essential for advancing precision neurology and personalizing patient care.

This review examines current breakthroughs in the understanding and treatment of Pompe disease, a genetic disorder caused by a deficiency in the GAA enzyme that leads to harmful glycogen buildup. The text highlights how early diagnosis is improving through umbilical cord blood testing in newborn screening, while next-generation enzyme replacement therapies (ERTs) like avalglucosidase alfa offer better outcomes for patients. Despite these medical gains, the sources emphasize that the central nervous system remains a difficult target for current drugs, prompting research into gene therapy and innovative delivery systems. Digital health technologies and advanced imaging are also featured as essential tools for detecting subtle motor decline before symptoms become severe. Finally, the research addresses the high economic burden of care and the importance of long-term monitoring for complications like cardiac conduction issues.

This academic review explores the complex landscape of secondary headache disorders, which are head pains caused by underlying medical conditions rather than being standalone diseases. The authors categorize these headaches into groups such as trauma, vascular issues, infections, and metabolic disturbances, highlighting that while they often mimic primary disorders like migraine, they can signal life-threatening emergencies. Effective diagnosis relies on identifying "red flags" and utilizing specific biomarkers, including neuroimaging and cerebrospinal fluid analysis, to uncover the root cause. Management typically prioritizes treating the primary illness, though persistent symptoms may require acute or preventive therapies tailored to the patient's specific headache phenotype. Ultimately, the text emphasizes that understanding these secondary triggers provides vital insights into the general pathophysiology of pain and reduces the global burden of neurological disability.

This paper details the results of a Phase 1-2 clinical trial investigating a new treatment for myotonic dystrophy type 1, a progressive and currently incurable neuromuscular disease. The study tested del-desiran, an innovative therapy that combines a monoclonal antibody with an oligonucleotide to target and reduce toxic genetic transcripts in muscle tissue. Researchers found that the drug successfully reached its target, leading to a significant reduction in DMPK mRNA levels and an improvement in protein splicing patterns. While most participants experienced only mild side effects, two serious adverse events were recorded, including a case of stroke-like symptoms. Despite these safety concerns, the trial's findings regarding improved muscle function and hand movement have prompted the initiation of larger, late-stage clinical studies. Ultimately, the data suggests that this targeted molecular approach may offer a viable path for treating the underlying cause of this debilitating condition.

This paper details the final long-term results of the VALOR study and its open-label extension, which investigated the efficacy of tofersen in adults with SOD1-ALS. Researchers compared patients who began the drug immediately to those who switched from a placebo after six months, finding that earlier treatment led to better outcomes in muscle strength, breathing, and physical function. A critical finding was the sustained reduction of neurofilament light chain levels, a biomarker indicating that the therapy successfully slowed nerve cell degeneration. While the disease is typically characterized by a rapid and fatal decline, some participants experienced a rare stabilization or improvement in their clinical symptoms over several years. The study concludes that tofersen significantly extends survival and offers a clear clinical justification for its use as a targeted therapy for this genetic form of ALS. Most side effects were related to the injection procedure or the illness itself, confirming a manageable safety profile for long-term use.

This systematic review explores the neurological manifestations of Whipple’s disease, a rare infection caused by the bacterium Tropheryma whipplei. The authors analyzed 168 cases to identify key movement disorders and oculomotor abnormalities, noting that supranuclear gaze palsy and myorhythmia are the most frequent diagnostic indicators. Specifically, the study emphasizes that unique symptoms like oculomasticatory myorhythmia are pathognomonic, meaning they specifically signal this condition even when typical digestive symptoms are missing. Diagnostic challenges are addressed, highlighting that while brain biopsies offer the highest accuracy, PCR testing of spinal fluid or saliva serves as a vital less-invasive tool. Finally, the research reviews evolving antibiotic treatments, showing a shift toward combining doxycycline and hydroxychloroquine to improve patient recovery and prevent fatal relapses.

This review examines acute disseminated encephalomyelitis (ADEM), a rare immune-mediated disorder characterized by widespread inflammation and demyelination in the central nervous system. Primarily affecting children, ADEM often follows an infectious or vaccine-related trigger, likely initiated by molecular mimicry where the immune system mistakenly attacks host myelin. The sources outline a broad range of potential causes, including viral, bacterial, and parasitic infections, as well as rare instances linked to vaccinations or organ transplants. Diagnosis relies heavily on magnetic resonance imaging (MRI) and the clinical presence of encephalopathy, as the disease lacks specific biomarkers and frequently overlaps with multiple sclerosis. While most cases are monophasic and respond well to high-dose corticosteroids, some patients experience relapses or severe variants like acute hemorrhagic leukoencephalitis. Recent research explores the role of anti-MOG antibodies and machine learning to improve diagnostic accuracy and long-term management strategies.

This medical text details the evaluation of abnormal spontaneous electromyographic (EMG) activity, which serves as a vital diagnostic indicator for various neuromuscular disorders. While healthy skeletal muscles typically remain electrically quiet at rest, the source identifies specific waveforms and firing patterns that signal underlying nerve or muscle pathology. It categorizes these irregularities into muscle fiber potentials, such as fibrillation and myotonic discharges, and motor unit potentials, including fasciculations and myokymia. Each phenomenon is distinguished by its unique morphology, frequency, and acoustic properties, helping clinicians determine the chronicity and severity of a lesion. Ultimately, the guide emphasizes that precise identification of these electrical signals is essential for accurate diagnosis and interprofessional management of complex neurological conditions.

The provided source is a comprehensive narrative review of Posterior Reversible Encephalopathy Syndrome (PRES), an acute neurological condition defined by brain edema and symptoms like seizures and headaches. It explores the pathophysiology of the disease, focusing on how high blood pressure and endothelial injury disrupt the blood-brain barrier. The text highlights that while the condition is often manageable through blood pressure stabilization and removing triggers, it carries significant risks of mortality and long-term impairment. Special attention is given to diagnostic challenges and the distinct ways the syndrome manifests in pediatric, obstetric, and transplant patients. Finally, the authors discuss the necessity of using MRI for accurate identification and suggest that future treatments may target specific molecular biomarkers.

This consensus statement provides a practical diagnostic framework to help general neurologists identify atypical parkinsonian disorders (APDs), such as progressive supranuclear palsy and multiple system atrophy. Because these conditions often mimic Parkinson’s disease but progress more rapidly and respond poorly to standard treatments, the authors offer an iterative algorithm based on clinical history, neurological exams, and non-contrast brain MRI. The guidelines highlight specific red flags—including early falls, eye movement abnormalities, and autonomic dysfunction—to facilitate earlier diagnosis and better patient support. By streamlining the evaluation process, the source aims to reduce diagnostic delays and avoid unnecessary testing while clarifying when to seek specialized tertiary referrals. The overview also addresses rare APDs and emerging biomarkers to ensure clinicians remain current with evolving scientific understandings.

This research study establishes a formal definition for refractory, intensive care–dependent NMDAR encephalitis (RI-NMDARE), identifying it as cases requiring over 90 days of ICU support despite second-line immunotherapy. The authors found that approximately 12% of severe patients fall into this high-risk category, which is characterized by a rapidly progressing disease and a higher prevalence of ovarian teratomas. Clinically, these patients often exhibit a specific triad of seizures, movement disorders, and dysautonomia, alongside elevated biological markers like CSF antibody titers and serum neurofilament levels. Despite receiving earlier and more aggressive treatments, individuals with this phenotype experience higher mortality rates and significantly poorer long-term recovery. The study suggests that early recognition of these clinical and biomarker profiles is vital for implementing targeted third-line therapies to improve outcomes. Ultimately, the findings highlight that treatment resistance may be driven by underlying immune mechanisms rather than delays in standard medical intervention.

This multicenter study investigates the prevalence and diagnostic utility of LRP4 antibodies in patients with suspected myasthenia gravis (MG). By comparing three different cell-based assay (CBA) protocols, researchers found that these antibodies are rare, appearing in only 2% of MG cases and even in some patients with unrelated neurological disorders. The results were highly inconsistent across testing methods, with the most common positive signals failing to appear when using live cell assays. These discrepancies suggest that methanol fixation may create false positives by exposing non-native protein structures. Consequently, the authors conclude that routine LRP4 testing currently lacks clinical value due to poor reproducibility and limited specificity. The findings emphasize an urgent need for standardized testing protocols before LRP4 can be considered a reliable biomarker for the disease.

This research study examines the incidence and severity of autoantibody-associated autoimmune encephalitis (AE) during the COVID-19 pandemic compared to a prepandemic period. Using data from 24 medical centers, researchers found that new hospital cases of AE actually decreased between 2020 and 2022, particularly those involving neuronal surface antibodies. The analysis suggests that SARS-CoV-2 infection and vaccination are not major triggers for this specific neurological condition, as disease severity, age, and sex distribution remained stable across both timeframes. Experts believe the observed decline in cases may have resulted from reduced hospital referrals or social distancing measures rather than a true drop in biological occurrence. Ultimately, the findings refute the hypothesis that the pandemic caused a surge in clinically definite autoimmune CNS diseases.

This 2025 academic review provides a comprehensive update on dermatomyositis (DM), an inflammatory disease primarily affecting the skin and skeletal muscles. The authors emphasize that specific skin lesions, such as Gottron papules and the heliotrope rash, are vital for early diagnosis and can signal serious risks like malignancy or lung disease. A major focus is placed on myositis-specific autoantibodies, which help clinicians predict disease severity and tailor treatments to individual patient profiles. Diagnostic advancements highlighted include muscle MRI patterning and MxA immunohistochemistry, which offer greater precision than traditional blood tests alone. Management strategies have shifted toward early immunosuppression, including the use of IVIG and JAK inhibitors to improve long-term outcomes. Ultimately, the source advocates for a multidisciplinary approach to address the complex systemic complications associated with this condition.

This research article advocates for a comprehensive shift in how medical professionals categorize and diagnose the neurological effects of HTLV-1. While the virus is traditionally linked to spinal cord disease, the authors introduce the HTLV-1 neurological complex to describe a broader range of symptoms, including cognitive decline, nerve damage, and muscle inflammation. This "iceberg model" suggests that many patients suffer from underrecognized conditions that extend well beyond classic paralysis. Because misdiagnosis is common in endemic regions like Latin America, the text emphasizes the need for early screening and multisystem evaluations. Current treatment relies on anti-inflammatory steroids, though emerging monoclonal antibody therapies show potential for slowing progression despite high costs. Ultimately, the source calls for global health priority and better clinical awareness to improve the lives of millions of infected individuals.

This research article presents a meta-analysis and systematic review investigating the effectiveness of alpha-lipoic acid (ALA) in treating diabetic peripheral neuropathy. The authors synthesize data from randomized controlled trials to determine how this antioxidant affects nerve damage symptoms, such as burning and numbness, alongside metabolic markers like fasting glucose and cholesterol. While the findings suggest that ALA supplementation can reduce certain types of neuropathic pain and improve lipid profiles, it appears to have no significant impact on long-term blood sugar levels measured via HbA1c. The study also catalogues adverse effects, noting that while generally safe, gastrointestinal issues like nausea are common at higher dosages. Ultimately, the researchers conclude that while ALA is a promising complementary therapy, the current evidence is limited by methodological heterogeneity and requires more robust, large-scale studies.

This article outlines a systematic approach for clinicians to identify the underlying causes of small fiber neuropathy (SFN), a condition where standard tests often fail to provide an etiology. The authors categorize diagnostic investigations into first-line blood tests, which screen for common metabolic, endocrine, and inflammatory triggers like diabetes, vitamin deficiencies, and autoimmune disorders. For complex cases, they propose second-line investigations involving specialized genetic testing and advanced biomarkers tailored to specific clinical warning signs. By providing a structured diagnostic algorithm, the text helps medical professionals move beyond a symptom-only diagnosis to find treatable origins. The research emphasizes that while many cases remain idiopathic, exhaustive screening for immunological and hereditary factors is essential for effective patient management. Ultimately, the source serves as a practical guide to rationalizing laboratory tests to improve the diagnostic yield in clinical practice.

This phase 3 clinical trial, known as TenCRAOS, investigated whether the drug tenecteplase could improve vision for patients suffering from acute central retinal artery occlusion. Researchers compared the efficacy and safety of a single intravenous injection of the thrombolytic agent against a standard dose of oral aspirin when administered within a tight 4.5-hour window. The study found that tenecteplase did not provide superior vision recovery compared to aspirin, with approximately one-fifth of patients in both groups achieving the primary visual milestone. Furthermore, the experimental treatment was linked to higher rates of serious adverse events, including a fatal brain hemorrhage. These results suggest that the risks of systemic thrombolysis may outweigh the benefits for this specific eye emergency. Consequently, the authors conclude that tenecteplase should not be routinely used for this condition based on current evidence.

This episodes summarizes three papers on significant advancements and clinical recommendations for utilizing blood-based biomarkers to diagnose Alzheimer’s disease and other neurodegenerative conditions. Research highlights how testing for proteins like p-tau217, amyloid-beta, and neurofilament light chain offers a less invasive, more affordable alternative to traditional spinal taps or PET scans. New clinical practice guidelines suggest that tests meeting specific accuracy thresholds can effectively triage patients or even substitute for older diagnostic methods in specialized memory clinics. However, experts emphasize that these tools must be part of a comprehensive medical evaluation and require standardized interpretation to manage potential diagnostic errors. Ethical considerations and the need for provider training remain central to integrating these scalable technologies into routine healthcare. Ongoing efforts focus on harmonizing laboratory methods to ensure consistent results across different testing platforms and global regions.

The 2026 American Heart Association and American Stroke Association guidelines provide a comprehensive framework for the early management of acute ischemic stroke. Developed by a multidisciplinary writing group, the document updates clinical protocols for prehospital coordination, emergency evaluation, and advanced reperfusion therapies. Key recommendations endorse the use of tenecteplase as an alternative to alteplase and emphasize the benefits of mobile stroke units and endovascular thrombectomy. Beyond initial treatment, the text outlines essential in-hospital supportive care, focusing on stroke unit organization, dysphagia screening, and the prevention of medical complications. These standards aim to reduce long-term disability and improve survival through systematic quality improvement and evidence-based practice.

This review explores multifocal motor neuropathy (MMN), a rare autoimmune condition characterized by progressive muscle weakness and motor conduction blocks. The paper details how the disease predominantly impacts the distal upper limbs of middle-aged men while sparing sensory functions. Electrodiagnostic testing, nerve ultrasound, and MRI serve as vital tools for identifying nerve enlargement and distinguishing MMN from similar disorders like ALS. Although high-titer anti-GM1 antibodies are found in some patients, the diagnosis relies heavily on specific clinical and electrical criteria. Immunoglobulin therapy remains the primary treatment for restoring strength, though many patients experience a very slow long-term decline. Future management may improve through complement inhibitors and other advanced immunotherapies designed to prevent permanent axonal damage.

Stiff-person syndrome (SPS) is a rare autoimmune neurological disorder primarily defined by muscle rigidity and painful spasms caused by impaired inhibitory neurotransmission. This comprehensive review details how the condition often involves antibodies against glutamic acid decarboxylase (GAD) and can manifest in various forms, ranging from classical stiffness to complex spectrum disorders that overlap with epilepsy or ataxia. Because early symptoms are frequently mistaken for psychiatric issues or other movement disorders, the authors emphasize the necessity of specialized antibody testing and electromyography for an accurate diagnosis. Management typically relies on a combination of GABA-ergic medications, such as diazepam and baclofen, alongside immunotherapies like intravenous immunoglobulin (IVIG) to modulate the immune response. Clinical outcomes vary, but the text highlights that early intervention and structured monitoring via tools like the BRIT questionnaire are vital for preventing long-term disability. Ultimately, the source provides a comprehensive framework for clinicians to recognize, diagnose, and treat the diverse phenotypes of this challenging disease.

This review article provides a comprehensive guide for diagnosing and managing dementia with Lewy bodies (DLB), a condition frequently prone to misidentification. The authors emphasize the importance of recognizing core clinical features, such as cognitive fluctuations, visual hallucinations, parkinsonism, and REM sleep behavior disorder. Beyond traditional symptoms, the text highlights prodromal markers like unexplained delirium and autonomic dysfunction to facilitate earlier detection. Specialized diagnostic tools, including DaTScans and polysomnography, are evaluated for their utility in distinguishing DLB from related neurodegenerative diseases. Finally, the sources advocate for a multidisciplinary management approach that combines careful pharmacological interventions with non-drug therapies to address the complex needs of patients.